Affiliation:
1. Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”
Abstract
Introduction. More and more studies demonstrate the importance of determining the beta-adrenergic reactivity of erythrocyte membranes (beta-ARM) for predicting the severity of cardiovascular diseases, including chronic heart failure. But the presence of general patterns between the change in beta-ARM and the expression of beta1adrenergic receptors on the membranes of cardiomyocytes, depending on the left ventricular ejection fraction (LVEF) remains questionable.Aim: To evaluate beta-ARM and expression of beta1-adrenergic receptors of cardiomyocytes in groups of patients with heart failure with preserved (≥ 50%) and reduced (< 50%) LV EF.Materials and methods. The study included 100 patients with chronic heart failure of ischemic origin. Groups of 79 patients with LVEF ≥ 50% and 21 patients with LVEF < 50% were formed. The levels of epinephrine and norepinephrine in blood plasma and the expression of beta1-adrenergic receptors in myocardial samples were assessed using enzyme immunoassay. Beta-ARM was determined in whole blood by assessing the inhibition of hemolysis of erythrocytes placed in a hypoosmotic medium in the presence of a selective beta-blocker.Results. In the group with LV EF < 50%, beta-ARM was increased (p = 0.037), amounting to 31.9% (23.2; 40.1), compared with the group with LVEF ≥ 50%, where beta-ARM was 21.4% (15.0; 31.7). At the same time, in patients with LV EF < 50%, the expression of beta1-AR on cardiomyocyte membranes was significantly lower than in the other group (p = 0.037): 2.7 (2.1; 3.0) ng/mg and 3.1 (2.4; 3.9) ng/mg total protein, respectively. However, plasma levels of epinephrine and noradrenaline were comparable in the study groups.Conclusion. Patients with heart failure with LVEF < 50% were characterized by increased beta-ARM and reduced expression of beta1-AR on cardiomyocyte membranes compared with the group with LVEF ≥ 50% with comparable levels of circulating catecholamines.
Publisher
Cardiology Research Institute
Subject
Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine
Reference13 articles.
1. Fayzulloev A.I., Shukurova S.M., Rashidov I.M., Radzhabova G.M. Chronic heart failure: current problems and the way to solve it. Herald of institute of postgraduate education in health sphere. 2021;(2):93–100. (In Russ.). URL: https://elibrary.ru/item.asp?id=47456873 (20.04.2023).
2. Koltsov A.V., Tyrenko V.V., Sarana A.M., Yazenok A.V., Kogan E.I., Chentsov D.V. Prevalence of heart failure in a megalopolis. Kardiologiia. 2022;62(12):50–56. (In Russ.). DOI: 10.18087/cardio.2022.12.n2294.
3. Hartupee J., Mann D.L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat. Rev. Cardiol. 2017;14(1):30–38. DOI: 10.1038/nrcardio.2016.163.
4. Agüero J., Almenar L., Montó F., Oliver E., Sánchez-Lázaro I., Vicente D. et al. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J. Card. Fail. 2012;18(1):53–61. DOI: 10.1016/j.cardfail.2011.10.008.
5. Wei W., Smrcka A.V. Subcellular β-adrenergic receptor signaling in cardiac physiology and disease. J. Cardiovasc. Pharmacol. 2022;80(3):334–341. DOI: 10.1097/FJC.0000000000001324.